Research and Application of CAR-T in Solid Tumor Clinical Settings
Qi Changsong, MD, Associate Chief Physician at Beijing Cancer Hospital, specializes in cellular immunotherapy for solid tumors and clinical research on novel anticancer drugs. He has published over 20 SCI papers as first/corresponding author in journals including The Lancet, Nature Medicine, and Journal of Clinical Oncology. Recipient of national-level young talent program support; Beijing Municipal Health Administration “Young Talent” program; Peking University Outstanding Young Physician and Clinical Scientist; Standing Committee Member of the Gastrointestinal Stromal Tumor Committee, Chinese Society of Clinical Oncology; Secretary-General of the Gastric Cancer Prevention and Treatment Committee, Beijing Cancer Prevention and Treatment Association.
Development and Clinical Translation of STAR-T Cell Immunotherapy Products
Zhao Xueqiang, Associate Researcher at Tsinghua University School of Medicine and Co-founder of Huaxia Yingtai Company. Ph.D. in Immunology from the Chinese Academy of Sciences, postdoctoral fellow at MD Anderson Cancer Center, Beijing Overseas High-Level Talent Expert. With nearly 20 years of deep expertise in immune cells, he has published over 30 papers, applied for more than 30 patents, and led/participated in over 10 major national and municipal projects, winning multiple scientific awards. In 2018, he co-founded Huaxia Yingtai to develop superior gene-edited T-cell therapeutics based on core technologies like STAR-T.
Report Time: November 20, 2025, 3:00 PM
Report Location: Room 302, Science and Technology Building
Invited by: Zhang Yi, Innovation Teaching and Research Studio